---
title: "REG - Hutchmed China Ltd - Vesting of awards under Long Term Incentive Plan"
description: "HUTCHMED (China) Limited announced the vesting of non-performance based awards under its Long Term Incentive Plan (LTIP) on October 20, 2025. The awards, granted on October 20, 2021, were vested to Dr"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262004846.md"
published_at: "2025-10-21T08:30:00.000Z"
---

# REG - Hutchmed China Ltd - Vesting of awards under Long Term Incentive Plan

> HUTCHMED (China) Limited announced the vesting of non-performance based awards under its Long Term Incentive Plan (LTIP) on October 20, 2025. The awards, granted on October 20, 2021, were vested to Dr. Dan Eldar, Ms. Edith Shih, and Professor Tony Mok, each receiving 1,938 American depositary shares (ADS). The transaction was conducted outside a trading venue, and the ADS represents five ordinary shares of US$0.10. HUTCHMED is a biopharmaceutical company focused on cancer and immunological disease therapies.

RNS Number : 0510E Hutchmed (China) Limited 21 October 2025

**Vesting of awards under the Long Term Incentive Plan**

Hong Kong, Shanghai & Florham Park, NJ - Tuesday, October 21, 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan ("LTIP") on October 20, 2021 to the following persons discharging managerial responsibilities were vested on October 20, 2025:-

Award Holder

Number of American depositary shares ("ADS")

Dr Dan Eldar (Non-executive Director ("NED"))

1,938

Ms Edith Shih (NED)

1,938 (1)

Professor Tony Mok (Independent Non-executive Director)

1,938

Note:

(1) These ADSs were not received by Ms Edith Shih, but were received by or for the account of her employer, Hutchison International Limited.

The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

(a) Dr Dan Eldar

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Dr Dan Eldar

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

HUTCHMED (China) Limited

b)

LEI

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

ADS each representing five Ordinary Shares of US$0.10

ADS ISIN: US44842L1035

b)

Nature of the transaction

Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

1,938 ADS

d)

Aggregated information

N/A

e)

Date of the transaction

2025-10-20

f)

Place of the transaction

Outside a trading venue

(b) Professor Tony Mok

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Professor Tony Mok

2

Reason for the notification

a)

Position/status

Independent Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

HUTCHMED (China) Limited

b)

LEI

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

ADS each representing five Ordinary Shares of US$0.10

ADS ISIN: US44842L1035

b)

Nature of the transaction

Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

1,938 ADS

d)

Aggregated information

N/A

e)

Date of the transaction

2025-10-20

f)

Place of the transaction

Outside a trading venue

**About HUTCHMED**

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

**CONTACTS**

Investor Enquiries

+852 2121 8200 / ir@hutch-med.com

Media Enquiries

FTI Consulting -

+44 20 3727 1030 / HUTCHMED@fticonsulting.com

Ben Atwell / Alex Shaw

+44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)

Brunswick - Zhou Yi

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Panmure Liberum

Nominated Advisor and Joint Broker

Atholl Tweedie / Emma Earl / Rupert Dearden

+44 20 7886 2500

Cavendish

Joint Broker

Geoff Nash / Nigel Birks

+44 20 7220 0500

Deutsche Numis

Joint Broker

Freddie Barnfield / Jeffrey Wong / Duncan Monteith

+44 20 7260 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DSHDZMZGGGRGKZM

### Related Stocks

- [00013.HK - HUTCHMED](https://longbridge.com/en/quote/00013.HK.md)
- [HCM.US - Hutchmed China](https://longbridge.com/en/quote/HCM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hutchmed China hails lung cancer trial results published in Lancet | Hutchmed China Ltd announced that results from its SACHI phase-three lung cancer trial have been published in The Lancet | [Link](https://longbridge.com/en/news/272549848.md) |
| HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event | - HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanis | [Link](https://longbridge.com/en/news/263921874.md) |
| James Van Der Beek Warned of the 1 Telling Cancer Symptom He Had Months Before His Death: ‘I Had No Idea… ‘ | James Van Der Beek, known for his roles in Dawson’s Creek and Varsity Blues, passed away at 48 from colorectal cancer. H | [Link](https://longbridge.com/en/news/275956382.md) |
| Teen girl whose Chicago father was detained in an immigration case dies from a rare cancer | Ofelia Giselle Torres Hidalgo, a 16-year-old from Chicago, has died from stage 4 alveolar rhabdomyosarcoma after advocat | [Link](https://longbridge.com/en/news/276014113.md) |
| Over $1.8M in donations pour in for James Van Der Beek's wife, 6 children | An online fundraiser was launched following the death of actor James Van Der Beek, who battled cancer. The GoFundMe, cre | [Link](https://longbridge.com/en/news/275917950.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
